Fetal Bovine Serum market Summary
According to MRFR analysis, the Fetal Bovine Serum Market Size was valued at USD 1.01 Billion in 2024 and the market is projected to grow from USD 1.072 Billion in 2025 to USD 1.946 Billion by 2035, registering a CAGR of 6.14% during the forecast period (2025–2035). North America led the market with over 64.36% share, generating around USD 0.65 Billion in revenue.
The Fetal Bovine Serum Market is expanding due to increasing demand for cell culture media in biotechnology and pharmaceutical research. Key trends include rising use in vaccine production, regenerative medicine, and biopharmaceutical development, along with growing investments in life science research and advancements in cell-based technologies globally.
Key Market Trends & Highlights
The Fetal Bovine Serum Market is experiencing a dynamic shift driven by ethical sourcing and technological advancements.
- North America remains the largest market for fetal bovine serum, driven by robust demand in research and development.
- Asia-Pacific is emerging as the fastest-growing region, with a market value of USD 0.3 billion in 2024, fueled by increasing investments in biotechnology.
- Heat inactivated fetal bovine serum continues to dominate the market, while tagged fetal bovine serum is witnessing rapid growth.
- Rising demand in biotechnology and increased investment in research and development are key drivers propelling market expansion.
Market Size & Forecast
| 2024 Market Size | 1.01 (USD Billion) |
| 2035 Market Size | 1.946 (USD Billion) |
| CAGR (2025 - 2035) | 6.14% |
Major Players
Companies such as Thermo Fisher Scientific (US), Bovogen Biologicals (AU), Serumwerk Bernburg AG (DE), Hyclone Laboratories (US), Gemini Bio-Products (US), Corning Incorporated (US), LGC Limited (GB), Biowest (FR), Fetal Bovine Serum (FBS) (US) are some of the major participants in the global market.